Assessment of Alzheimer’s disease-related biomarkers in patients with obstructive sleep apnea: A systematic review and meta-analysis

Assessment of Alzheimer’s disease-related biomarkers in patients with obstructive sleep apnea: A systematic review and meta-analysis

Increasing evidence links Alzheimer’s disease (AD) to various sleep disorders, including obstructive sleep apnea (OSA). The core AD cerebrospinal fluid (CSF) biomarkers, including amyloid-β 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau), can reflect key elements of AD pathophysiology b...

Full description

Bibliographic Details
Main Authors:	Wenqi Cui, Zhenghao Duan, Zijian Li, Juan Feng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-10-01
Series:	Frontiers in Aging Neuroscience
Subjects:	obstructive sleep apnea Alzheimer’s disease amyloid-β 42 (Aβ42) total tau phosphorylated tau (p-tau) PET scans
Online Access:	https://www.frontiersin.org/articles/10.3389/fnagi.2022.902408/full

Similar Items

Associations between risk of Alzheimer's disease and obstructive sleep apnea, intermittent hypoxia, and arousal responses: A pilot study
by: Cheng-Yu Tsai, et al.
Published: (2022-11-01)

Alzheimer’s Disease CSF Biomarkers as Possible Indicators of Tap-Test Response in Idiopathic Normal Pressure Hydrocephalus
by: Efstratios-Stylianos Pyrgelis, et al.
Published: (2023-11-01)

Anesthesia and surgery-induced elevation of CSF sTREM2 is associated with early cognitive dysfunction after thoracoabdominal aortic dissection surgery
by: Kexin Wang, et al.
Published: (2022-12-01)

Continuous Positive Airway Pressure Reduces Plasma Neurochemical Levels in Patients with OSA: A Pilot Study
by: Wen-Te Liu, et al.
Published: (2023-02-01)

Alzheimer’s disease biomarkers in cerebrospinal fluid are stable with the Elecsys immunoassay to most pre-analytical influencing factors except freezing at -80 °C
by: Franz Felix Konen, et al.
Published: (2023-06-01)

The relationship between obstructive sleep apnea and circulating tau levels: A meta‐analysis
by: Zhi‐Wei Huang, et al.
Published: (2023-04-01)

Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology
by: Daniel J. Figdore, et al.
Published: (2024-01-01)

Alzheimer’s Disease: Models and Molecular Mechanisms Informing Disease and Treatments
by: Kaden L. Nystuen, et al.
Published: (2024-01-01)

Dietary glucosinolates derived isothiocyanates: chemical properties, metabolism and their potential in prevention of Alzheimer’s disease
by: Farhana Khan, et al.
Published: (2023-07-01)

Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
by: Niklas Mattsson‐Carlgren, et al.
Published: (2021-06-01)

Advantages and Pitfalls in Fluid Biomarkers for Diagnosis of Alzheimer’s Disease
by: Syed Haris Omar, et al.
Published: (2020-07-01)

Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels
by: Taylor J. Maxwell, et al.
Published: (2018-08-01)

Aβ1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis
by: Débora Lanznaster, et al.
Published: (2020-04-01)

Cerebrospinal and Blood Biomarkers in Alzheimer’s Disease: Did Mild Cognitive Impairment Definition Affect Their Clinical Usefulness?
by: Giulia Bivona, et al.
Published: (2023-11-01)

Initial levels of β-amyloid and tau deposition have distinct effects on longitudinal tau accumulation in Alzheimer’s disease
by: Yue Cai, et al.
Published: (2023-02-01)

High Cerebrospinal Fluid CX3CL1 Levels in Alzheimer’s Disease Patients but Not in Non-Alzheimer’s Disease Dementia
by: Giulia Bivona, et al.
Published: (2022-09-01)

Plasma Biomarkers Ascertained With Immunomagnetic Reduction Diagnosing Early-Stage Alzheimer's Disease: A Systematic Review
by: Pui-Un Tang, et al.
Published: (2021-01-01)

Diagnostic Accuracy of the Five-Word Test for Mild Cognitive Impairment Due to Alzheimer’s Disease
by: Chiara Fornari, et al.
Published: (2022-04-01)

Aβ and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer’s Disease
by: Yuanxin Zhao, et al.
Published: (2022-07-01)

Different associations between amyloid-βeta 42, amyloid-βeta 40, and amyloid-βeta 42/40 with soluble phosphorylated-tau and disease burden in Alzheimer’s disease: a cerebrospinal fluid and fluorodeoxyglucose-positron emission tomography study
by: Caterina Motta, et al.
Published: (2023-08-01)

Analysis of Risk Factors for Cerebral Microbleeds and the Relationship between Cerebral Microbleeds and Cognitive Impairment
by: Huiwen Zheng, et al.
Published: (2022-10-01)

Research advances in the study of sleep disorders, circadian rhythm disturbances and Alzheimer’s disease
by: Xiangyang Xiong, et al.
Published: (2022-08-01)

Effects of early tooth loss on chronic stress and progression of neuropathogenesis of Alzheimer’s disease in adult Alzheimer’s model AppNL-G-F mice
by: Suzuko Ochi, et al.
Published: (2024-02-01)

Protein Biomarkers for the Diagnosis of Alzheimer’s Disease at Different Stages of Neurodegeneration
by: Mar Pérez, et al.
Published: (2020-09-01)

Neuropathology, Neuroimaging, and Fluid Biomarkers in Alzheimer’s Disease
by: Helena Colvee-Martin, et al.
Published: (2024-03-01)

Pyroptosis as a candidate therapeutic target for Alzheimer’s disease
by: Yuehua Huang, et al.
Published: (2022-09-01)

The emerging double-edged sword role of exosomes in Alzheimer’s disease
by: Tao Liang, et al.
Published: (2023-06-01)

PICALM rs3851179 Variants Modulate Left Postcentral Cortex Thickness, CSF Amyloid β42, and Phosphorylated Tau in the Elderly
by: Zhiwei Wu, et al.
Published: (2022-12-01)

H2O2‐responsive multifunctional nanocomposite for the inhibition of amyloid‐β and Tau aggregation in Alzheimer's disease
by: Luying Qiao, et al.
Published: (2023-03-01)

Dual regulatory effects of neferine on amyloid-β and tau aggregation studied by in silico, in vitro, and lab-on-a-chip technology
by: Yunkwon Nam, et al.
Published: (2024-03-01)

Sleep deprivation: A risk factor for the pathogenesis and progression of Alzheimer's disease
by: Zhengyun Han, et al.
Published: (2024-04-01)

Research Progress of Pyroptosis in Alzheimer’s Disease
by: Weiyue Xue, et al.
Published: (2022-06-01)

Neuropsychological, plasma marker, and functional connectivity changes in Alzheimer’s disease patients infected with COVID-19
by: Shouzi Zhang, et al.
Published: (2023-12-01)

Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease
by: Yinyi Xiong, et al.
Published: (2021-09-01)

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
by: Anna Rubinski, et al.
Published: (2022-09-01)

Serum neurofilament light reflects cognitive dysfunctions in children with obstructive sleep apnea
by: Yewen Shi, et al.
Published: (2022-07-01)

Mouse Models of Alzheimer’s Disease
by: Miyabishara Yokoyama, et al.
Published: (2022-06-01)

Association between Sleep, Alzheimer’s, and Parkinson’s Disease
by: Sumire Matsumoto, et al.
Published: (2021-11-01)

Gut Microbiota and Immunotherapy for Alzheimer’s Disease
by: Chun-Ling Dai, et al.
Published: (2022-12-01)

Curcuminoids and resveratrol as anti-Alzheimer agents
by: Oliver B. Villaflores, et al.
Published: (2012-12-01)